Prof Steven Lamberts talks about the role of managing patient hormone levels in the treatment of Cushing’s disease and discusses the promising results of clinical trials investigating pasireotide. Prof Lamberts explains how neuroendocrine tumours, along with all metastatic deposits, can be targeted using somatostatin analogues coupled to radionucleotides and outlines his hopes for the development of this new technique.